Pavel Zrazhevskiy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Pavel Zrazhevskiy has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Xiaohu Gao
Department of Bioengineering, University of Washington, Seattle, WA 98195, USA
13 shared publications Xiaohu Gao
Department of Bioengineering; University of Washington; Seattle WA 98195 USA
6 shared publicationsJunwei Li
Department of Bioengineering; University of Washington; Seattle WA 98195 USA
4 shared publications- Anjun Qin
South China University of Technology
2 shared publications - Ben Zhong Tang
The Chinese University of Hong Kong
2 shared publications Carrie Y. K. Chan
Department of Chemistry, Institute for Advanced Study, Institute of Molecular Functional Materials, and State Key Laboratory of Molecular Neuroscience The Hong Kong University of Science & Technology Clear Water Bay, Kowloon, Hong Kong (China)
2 shared publications
Latest Publications
- 6 July 2017
- Published by Oxford University Press (OUP)
Bioconjugated quantum dots for tumor molecular imaging and profiling
This article discusses the use of bioconjugated quantum dots (QDs) for tumor molecular imaging and profiling. The need for personalized diagnostics and therapy is becoming apparent in all areas of medicine, and especially urgent and sought after in treating cancer. Mechanisms of cancerogenesis and cancer response to therapy remain poorly understood, thus precluding accurate cancer diagnosis, prognosis, and effective treatment. Accurate molecular profiling of individual tumors is one key to effective treatment. This article first considers the photophysical properties of QDs before reviewing the most common methods for engineering QD-based probes for biomedical applications, including water solubilization and bioconjugation approaches. It also describes a number of techniques for molecular imagingand profiling of tumors, ranging from QD-based multicolor flow cytometry and applications of QDs in high-resolution correlated fluorescence/electron microscopy, QD bioprobes for molecular profiling of tumor-tissue sections and microarrays, and QD-oligonucleotide bioconjugates for in-situ hybridization.
- 6 July 2017
- Published by Oxford University Press (OUP)
Bioconjugated quantum dots for tumor molecular imaging and profiling
This article discusses the use of bioconjugated quantum dots (QDs) for tumor molecular imaging and profiling. The need for personalized diagnostics and therapy is becoming apparent in all areas of medicine, and especially urgent and sought after in treating cancer. Mechanisms of cancerogenesis and cancer response to therapy remain poorly understood, thus precluding accurate cancer diagnosis, prognosis, and effective treatment. Accurate molecular profiling of individual tumors is one key to effective treatment. This article first considers the photophysical properties of QDs before reviewing the most common methods for engineering QD-based probes for biomedical applications, including water solubilization and bioconjugation approaches. It also describes a number of techniques for molecular imagingand profiling of tumors, ranging from QD-based multicolor flow cytometry and applications of QDs in high-resolution correlated fluorescence/electron microscopy, QD bioprobes for molecular profiling of tumor-tissue sections and microarrays, and QD-oligonucleotide bioconjugates for in-situ hybridization.
- 7 June 2016
- Published by Wiley in Angewandte Chemie
- Vol. 128 (31) , 9121-9124
Cross‐Platform DNA Encoding for Single‐Cell Imaging of Gene Expression
- 7 June 2016
- Published by Wiley in Angewandte Chemie
- Vol. 128 (31) , 9121-9124
Cross‐Platform DNA Encoding for Single‐Cell Imaging of Gene Expression
- 7 June 2016
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 55 (31) , 8975-8978
Cross‐Platform DNA Encoding for Single‐Cell Imaging of Gene Expression
Integration of imaging data across different molecular target types can provide in‐depth insight into cell physiology and pathology, but remains challenging owing to poor compatibility between target‐type‐specific labeling methods. We show that cross‐platform imaging analysis can be readily achieved through DNA encoding of molecular targets, which translates the molecular identity of various target types into a uniform in situ array of ssDNA tags for subsequent labeling with complementary imaging probes. The concept was demonstrated through multiplexed imaging of mRNAs and their corresponding proteins with multicolor quantum dots. The results reveal heterogeneity of cell transfection with siRNA and outline disparity in RNA interference (RNAi) kinetics at the level of both the mRNA and the encoded protein.
- 7 June 2016
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 55 (31) , 8975-8978
Cross‐Platform DNA Encoding for Single‐Cell Imaging of Gene Expression
Integration of imaging data across different molecular target types can provide in‐depth insight into cell physiology and pathology, but remains challenging owing to poor compatibility between target‐type‐specific labeling methods. We show that cross‐platform imaging analysis can be readily achieved through DNA encoding of molecular targets, which translates the molecular identity of various target types into a uniform in situ array of ssDNA tags for subsequent labeling with complementary imaging probes. The concept was demonstrated through multiplexed imaging of mRNAs and their corresponding proteins with multicolor quantum dots. The results reveal heterogeneity of cell transfection with siRNA and outline disparity in RNA interference (RNAi) kinetics at the level of both the mRNA and the encoded protein.
Eliminating Size-Associated Diffusion Constraints for Rapid On-Surface Bioassays with Nanoparticle Probes
Nanoparticle probes enable implementation of advanced on‐surface assay formats, but impose often underappreciated size‐associated constraints, in particular on assay kinetics and sensitivity. The present study highlights substantially slower diffusion‐limited assay kinetics due to the rapid development of a nanoprobe depletion layer next to the surface, which static incubation and mixing of bulk solution employed in conventional assay setups often fail to disrupt. In contrast, cyclic solution draining and replenishing yields reaction‐limited assay kinetics irrespective of the probe size. Using common surface bioassays, enzyme‐linked immunosorbent assays and immunofluorescence, this study shows that this conceptually distinct approach effectively “erases” size‐dependent diffusion constraints, providing a straightforward route to rapid on‐surface bioassays employing bulky probes and procedures involving multiple labeling cycles, such as multicycle single‐cell molecular profiling. For proof‐of‐concept, the study demonstrates that the assay time can be shortened from hours to minutes with the same probe concentration and, at a typical incubation time, comparable target labeling can be achieved with up to eight times lower nanoprobe concentration. The findings are expected to enable realization of novel assay formats and stimulate development of rapid on‐surface bioassays with nanoparticle probes.
Eliminating Size-Associated Diffusion Constraints for Rapid On-Surface Bioassays with Nanoparticle Probes
Nanoparticle probes enable implementation of advanced on‐surface assay formats, but impose often underappreciated size‐associated constraints, in particular on assay kinetics and sensitivity. The present study highlights substantially slower diffusion‐limited assay kinetics due to the rapid development of a nanoprobe depletion layer next to the surface, which static incubation and mixing of bulk solution employed in conventional assay setups often fail to disrupt. In contrast, cyclic solution draining and replenishing yields reaction‐limited assay kinetics irrespective of the probe size. Using common surface bioassays, enzyme‐linked immunosorbent assays and immunofluorescence, this study shows that this conceptually distinct approach effectively “erases” size‐dependent diffusion constraints, providing a straightforward route to rapid on‐surface bioassays employing bulky probes and procedures involving multiple labeling cycles, such as multicycle single‐cell molecular profiling. For proof‐of‐concept, the study demonstrates that the assay time can be shortened from hours to minutes with the same probe concentration and, at a typical incubation time, comparable target labeling can be achieved with up to eight times lower nanoprobe concentration. The findings are expected to enable realization of novel assay formats and stimulate development of rapid on‐surface bioassays with nanoparticle probes.
- Open Access
- 2 September 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 13651
Multiplexed In-cell Immunoassay for Same-sample Protein Expression Profiling
In-cell immunoassays have become a valuable tool for protein expression analysis complementary to established assay formats. However, comprehensive molecular characterization of individual specimens has proven challenging and impractical due to, in part, a singleplex nature of reporter enzymes and technical complexity of alternative assay formats. Herein, we describe a simple and robust methodology for multiplexed protein expression profiling on the same intact specimen, employing a well-characterized enzyme alkaline phosphatase for accurate quantification of all targets of interest, while overcoming fundamental limitations of enzyme-based techniques by implementing the DNA-programmed release mechanism for segregation of sub-sets of target-bound reporters. In essence, this methodology converts same-sample multi-target labeling into a set of isolated singleplex measurements performed in a parallel self-consistent fashion. For a proof-of-principle, multiplexed detection of three model proteins was demonstrated on cultured HeLa cells and two clinically-relevant markers of dementia, β-amyloid and PHF-tau, were profiled in formalin-fixed paraffin embedded brain tissue sections, uncovering correlated increase in abundance of both markers in the “Alzheimer’s disease” cohort. Featuring an analytically powerful yet technically simple and robust methodology, multiplexed in-cell immunoassay is expected to enable insightful same-sample protein profiling studies and become broadly adopted in biomedical research and clinical diagnostics.
- 2 September 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 13651
Open AccessMultiplexed In-cell Immunoassay for Same-sample Protein Expression Profiling
In-cell immunoassays have become a valuable tool for protein expression analysis complementary to established assay formats. However, comprehensive molecular characterization of individual specimens has proven challenging and impractical due to, in part, a singleplex nature of reporter enzymes and technical complexity of alternative assay formats. Herein, we describe a simple and robust methodology for multiplexed protein expression profiling on the same intact specimen, employing a well-characterized enzyme alkaline phosphatase for accurate quantification of all targets of interest, while overcoming fundamental limitations of enzyme-based techniques by implementing the DNA-programmed release mechanism for segregation of sub-sets of target-bound reporters. In essence, this methodology converts same-sample multi-target labeling into a set of isolated singleplex measurements performed in a parallel self-consistent fashion. For a proof-of-principle, multiplexed detection of three model proteins was demonstrated on cultured HeLa cells and two clinically-relevant markers of dementia, β-amyloid and PHF-tau, were profiled in formalin-fixed paraffin embedded brain tissue sections, uncovering correlated increase in abundance of both markers in the “Alzheimer’s disease” cohort. Featuring an analytically powerful yet technically simple and robust methodology, multiplexed in-cell immunoassay is expected to enable insightful same-sample protein profiling studies and become broadly adopted in biomedical research and clinical diagnostics.
- 10 November 2014
- Published by Wiley in Particle & Particle Systems Characterization
- Vol. 31 (12) , 1291-1299
Addressing Key Technical Aspects of Quantum Dot Probe Preparation for Bioassays
Fluorescent semiconductor nanoparticles, or quantum dots, have become a promising platform for the engineering of biofunctional probes for a variety of biomedical applications, ranging from multicolor imaging to single‐molecule tracking to traceable drug delivery. Advances in organometallic synthesis have enabled preparation of hydrophobic quantum dots with high quantum yields and narrow size distribution, offering bright optical materials with narrow size‐tunable emission profiles. At the same time, polymer encapsulation procedures provide a simple and versatile methodology for transferring hydrophobic nanoparticles into physiologically relevant aqueous buffers. Taken together, hydrophobic nanoparticle platforms and polymer encapsulation should offer great flexibility for implementation of novel probe designs. However, the success of the encapsulation and purification depends on many factors often overlooked in the scientific literature, such as close match between nanoparticle and polymer physicochemical properties and dimensions, slow dynamics of polymer arrangement on the nanoparticle surface, and the size and charge similarity of resultant polymer‐coated quantum dots and empty byproduct polymer micelles. To make this general hydrophobic nanoparticle modification strategy accessible by a broad range of biomedical research groups, we focus on the important technical aspects of nanoparticle polymer encapsulation, purification, bioconjugation, and characterization.
- 10 November 2014
- Published by Wiley in Particle & Particle Systems Characterization
- Vol. 31 (12) , 1291-1299
Addressing Key Technical Aspects of Quantum Dot Probe Preparation for Bioassays
Fluorescent semiconductor nanoparticles, or quantum dots, have become a promising platform for the engineering of biofunctional probes for a variety of biomedical applications, ranging from multicolor imaging to single‐molecule tracking to traceable drug delivery. Advances in organometallic synthesis have enabled preparation of hydrophobic quantum dots with high quantum yields and narrow size distribution, offering bright optical materials with narrow size‐tunable emission profiles. At the same time, polymer encapsulation procedures provide a simple and versatile methodology for transferring hydrophobic nanoparticles into physiologically relevant aqueous buffers. Taken together, hydrophobic nanoparticle platforms and polymer encapsulation should offer great flexibility for implementation of novel probe designs. However, the success of the encapsulation and purification depends on many factors often overlooked in the scientific literature, such as close match between nanoparticle and polymer physicochemical properties and dimensions, slow dynamics of polymer arrangement on the nanoparticle surface, and the size and charge similarity of resultant polymer‐coated quantum dots and empty byproduct polymer micelles. To make this general hydrophobic nanoparticle modification strategy accessible by a broad range of biomedical research groups, we focus on the important technical aspects of nanoparticle polymer encapsulation, purification, bioconjugation, and characterization.
- 31 October 2014
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 53 (49) , 13518-13522
An Aggregation‐Induced‐Emission Platform for Direct Visualization of Interfacial Dynamic Self‐Assembly
An in‐depth understanding of dynamic interfacial self‐assembly processes is essential for a wide range of topics in theoretical physics, materials design, and biomedical research. However, direct monitoring of such processes is hampered by the poor imaging contrast of a thin interfacial layer. We report in situ imaging technology capable of selectively highlighting self‐assembly at the phase boundary in real time by employing the unique photophysical properties of aggregation‐induced emission. Its application to the study of breath‐figure formation, an immensely useful yet poorly understood phenomenon, provided a mechanistic model supported by direct visualization of all main steps and fully corroborated by simulation and theoretical analysis. This platform is expected to advance the understanding of the dynamic phase‐transition phenomena, offer insights into interfacial biological processes, and guide development of novel self‐assembly technologies.
- 31 October 2014
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 53 (49) , 13518-13522
An Aggregation‐Induced‐Emission Platform for Direct Visualization of Interfacial Dynamic Self‐Assembly
An in‐depth understanding of dynamic interfacial self‐assembly processes is essential for a wide range of topics in theoretical physics, materials design, and biomedical research. However, direct monitoring of such processes is hampered by the poor imaging contrast of a thin interfacial layer. We report in situ imaging technology capable of selectively highlighting self‐assembly at the phase boundary in real time by employing the unique photophysical properties of aggregation‐induced emission. Its application to the study of breath‐figure formation, an immensely useful yet poorly understood phenomenon, provided a mechanistic model supported by direct visualization of all main steps and fully corroborated by simulation and theoretical analysis. This platform is expected to advance the understanding of the dynamic phase‐transition phenomena, offer insights into interfacial biological processes, and guide development of novel self‐assembly technologies.
- 31 October 2014
- Published by Wiley in Angewandte Chemie
- Vol. 126 (49) , 13736-13740
An Aggregation-Induced-Emission Platform for Direct Visualization of Interfacial Dynamic Self-Assembly
- 31 October 2014
- Published by Wiley in Angewandte Chemie
- Vol. 126 (49) , 13736-13740
An Aggregation-Induced-Emission Platform for Direct Visualization of Interfacial Dynamic Self-Assembly
- Open Access
- 10 July 2014
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 25 (8) , 1511-1516
Solid-Phase Bioconjugation of Heterobifunctional Adaptors for Versatile Assembly of Bispecific Targeting Ligands
High-throughput generation of bispecific molecules promises to expedite the discovery of new molecular therapeutics and guide engineering of novel multifunctional constructs. However, high synthesis complexity and cost have hampered the discovery of bispecific molecules in drug development and biomedical research. Herein we describe a simple solid-phase bioconjugation procedure for preparation of Protein A(G,L)-PEG-Streptavidin heterobifunctional adaptors (with 1:1:1 stoichiometry), which enable self-assembly of unmodified antibodies and biotinylated molecules into bispecific targeting ligands in a versatile mix-and-use manner. Utility of such adaptors is demonstrated by assembly of anti-CD3 and anti-Her2 antibodies into bispecific CD3xHer2 targeting ligands, which efficiently drive T-cell-mediated lysis of Her2-positive cancer cells. In comparison to bioconjugation in solution, the solid-phase procedure described here offers precise stoichiometry control, ease of purification, and high yield of functional conjugates. Simplicity and versatility should prove this methodology instrumental for preparation of bispecific ligands, as well as for high-throughput screening of bispecific combinations, before proceeding to synthesis of lead candidates via recombinant engineering or chemical cross-linking.
- 10 July 2014
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 25 (8) , 1511-1516
Open AccessSolid-Phase Bioconjugation of Heterobifunctional Adaptors for Versatile Assembly of Bispecific Targeting Ligands
High-throughput generation of bispecific molecules promises to expedite the discovery of new molecular therapeutics and guide engineering of novel multifunctional constructs. However, high synthesis complexity and cost have hampered the discovery of bispecific molecules in drug development and biomedical research. Herein we describe a simple solid-phase bioconjugation procedure for preparation of Protein A(G,L)-PEG-Streptavidin heterobifunctional adaptors (with 1:1:1 stoichiometry), which enable self-assembly of unmodified antibodies and biotinylated molecules into bispecific targeting ligands in a versatile mix-and-use manner. Utility of such adaptors is demonstrated by assembly of anti-CD3 and anti-Her2 antibodies into bispecific CD3xHer2 targeting ligands, which efficiently drive T-cell-mediated lysis of Her2-positive cancer cells. In comparison to bioconjugation in solution, the solid-phase procedure described here offers precise stoichiometry control, ease of purification, and high yield of functional conjugates. Simplicity and versatility should prove this methodology instrumental for preparation of bispecific ligands, as well as for high-throughput screening of bispecific combinations, before proceeding to synthesis of lead candidates via recombinant engineering or chemical cross-linking.